|
1
|
Dwivedi SKD, Rao G, Dey A, Mukherjee P,
Wren JD and Bhattacharya R: Small non-coding-RNA in gynecological
malignancies. Cancers. 13:10852021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brooks RA, Fleming GF, Lastra RR, Lee NK,
Moroney JW, Son CH, Tatebe K and Veneris JL: Current
recommendations and recent progress in endometrial cancer. CA
Cancer J Clin. 69:258–279. 2019.PubMed/NCBI
|
|
3
|
Tsikouras P, Zervoudis S, Manav B, Tomara
E, Iatrakis G, Romanidis C, Bothou A and Galazios G: Cervical
cancer: Screening, diagnosis and staging. J BUON. 21:320–325.
2016.PubMed/NCBI
|
|
4
|
Stewart C, Ralyea C and Lockwood S:
Ovarian cancer: An integrated review. Semin Oncol Nurs. 35:151–156.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shafabakhsh R and Asemi Z: Quercetin: A
natural compound for ovarian cancer treatment. J Ovarian Res.
12:552019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cree IA, White VA, Indave BI and Lokuhetty
D: Revising the WHO classification: Female genital tract tumours.
Histopathology. 76:151–156. 2020. View Article : Google Scholar
|
|
7
|
Devouassoux-Shisheboran M and Genestie C:
Pathobiology of ovarian carcinomas. Chin J Cancer. 34:50–55. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vergote I, González-Martín A, Ray-Coquard
I, Harter P, Colombo N, Pujol P, Lorusso D, Mirza MR, Brasiuniene
B, Madry R, et al: European experts consensus: BRCA/homologous
recombination deficiency testing in first-line ovarian cancer. Ann
Oncol. 33:276–287. 2022. View Article : Google Scholar
|
|
9
|
Steinberga I, Jansson K and Sorbe B:
Quality indicators and survival outcome in Stage IIIB-IVB
epithelial ovarian cancer treated at a single institution. In Vivo.
33:1521–1530. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang C and Liu N: Noncoding RNAs in the
glycolysis of ovarian cancer. Front Pharmacol. 13:8554882022.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Saslow D, Solomon D, Lawson HW, Killackey
M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur
DC, et al: American Cancer Society, American Society for Colposcopy
and cervical pathology, and American Society for Clinical Pathology
screening guidelines for the prevention and early detection of
cervical cancer. CA Cancer J Clin. 62:147–172. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu HH, Wang K, Feng XJ, Dong SS, Lin A,
Zheng LZ and Yan WH: Prevalence of human papillomavirus genotypes
and relative risk of cervical cancer in China: A systematic review
and meta-analysis. Oncotarget. 9:15386–15397. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bray F, Carstensen B, Møller H, Zappa M,
Zakelj MP, Lawrence G, Hakama M and Weiderpass E: Incidence trends
of adenocarcinoma of the cervix in 13 European countries. Cancer
Epidemiol Biomarkers Prev. 14:2191–2199. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li H, Wu X and Cheng X: Advances in
diagnosis and treatment of metastatic cervical cancer. J Gynecol
Oncol. 27:e432016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Crosbie EJ, Einstein MH, Franceschi S and
Kitchener HC: Human papillomavirus and cervical cancer. Lancet.
382:889–899. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Han X, Wen H, Ju X, Chen X, Ke G, Zhou Y,
Li J, Xia L, Tang J, Liang S and Wu X: Predictive factors of
para-aortic lymph nodes metastasis in cervical cancer patients: A
retrospective analysis based on 723 para-aortic lymphadenectomy
cases. Oncotarget. 8:51840–51847. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ferlay J, Colombet M, Soerjomataram I,
Dyba T, Randi G, Bettio M, Gavin A, Visser O and Bray F: Cancer
incidence and mortality patterns in Europe Estimates for 40
countries and 25 major cancers in 2018. Eur J Cancer. 103:356–387.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Koh WJ, Abu-Rustum NR, Bean S, Bradley K,
Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, et al:
Uterine neoplasms, version 1.2018, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 16:170–199. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kajo K, Vallová M, Biró C, Bognár G,
Macháleková K, Závodná K, Galbavý Š and Žúbor P: Molecular
pathology of endometrial carcinoma-a review. Cesk Patol. 51:65–73.
2015.In Czech.
|
|
21
|
Miccò M, Sala E, Lakhman Y, Hricak H and
Vargas HA: Imaging features of uncommon gynecologic cancers. AJR Am
J Roentgenol. 205:1346–1359. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Di Fiore R, Suleiman S, Pentimalli F,
O'Toole SA, O'Leary JJ, Ward MP, Conlon NT, Sabol M, Ozretić P,
Erson-Bensan AE, et al: Could MicroRNAs be useful tools to improve
the diagnosis and treatment of rare gynecological cancers? A Brief
overview. Int J Mol Sci. 22:38222021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mbatani N, Olawaiye AB and Prat J: Uterine
sarcomas. Int J Gynaecol Obstet. 143(Suppl 2): S51–S58. 2018.
View Article : Google Scholar
|
|
24
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Griffiths-Jones S: The microRNA registry.
Nucleic Acids Res. 32(Database Issue): D109–D111. 2004. View Article : Google Scholar :
|
|
26
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim VN: MicroRNA biogenesis: Coordinated
cropping and dicing. Nat Rev Mol Cell Biol. 6:376–385. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Carthew RW and Sontheimer EJ: Origins and
mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Riedmann LT and Schwentner R: miRNA,
siRNA, piRNA and argonautes: News in small matters. RNA Biol.
7:133–139. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Brennecke J, Hipfner DR, Stark A, Russell
RB and Cohen SM: Bantam encodes a developmentally regulated
microRNA that controls cell proliferation and regulates the
proapoptotic gene hid in Drosophila. Cell. 113:25–36. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zeng Y, Wagner EJ and Cullen BR: Both
natural and designed micro RNAs can inhibit the expression of
cognate mRNAs when expressed in human cells. Mol Cell. 9:1327–1333.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Doench JG, Petersen CP and Sharp PA:
siRNAs can function as miRNAs. Genes Dev. 17:438–442. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu P, Vernooy SY, Guo M and Hay BA: The
drosophila microRNA Mir-14 suppresses cell death and is required
for normal fat metabolism. Curr Biol. 13:790–795. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Krützfeldt J and Stoffel M: MicroRNAs: A
new class of regulatory genes affecting metabolism. Cell Metab.
4:9–12. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gao P, Tchernyshyov I, Chang TC, Lee YS,
Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT and
Dang CV: c-Myc suppression of miR-23a/b enhances mitochondrial
glutaminase expression and glutamine metabolism. Nature.
458:762–765. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Warburg O: The chemical constitution of
respiration ferment. Science. 68:437–443. 1928. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rolfe DF and Brown GC: Cellular energy
utilization and molecular origin of standard metabolic rate in
mammals. Physiol Rev. 77:731–758. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
DeBerardinis RJ, Mancuso A, Daikhin E,
Nissim I, Yudkoff M, Wehrli S and Thompson CB: Beyond aerobic
glycolysis: Transformed cells can engage in glutamine metabolism
that exceeds the requirement for protein and nucleotide synthesis.
Proc Natl Acad Sci USA. 104:19345–19350. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fantin VR, St-Pierre J and Leder P:
Attenuation of LDH-A expression uncovers a link between glycolysis,
mitochondrial physiology, and tumor maintenance. Cancer Cell.
9:425–434. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shim H, Chun YS, Lewis BC and Dang CV: A
unique glucose-dependent apoptotic pathway induced by c-Myc. Proc
Natl Acad Sci USA. 95:1511–1516. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Birsoy K, Wang T, Chen WW, Freinkman E,
Abu-Remaileh M and Sabatini DM: An essential role of the
mitochondrial electron transport Chain in cell proliferation is to
enable aspartate synthesis. Cell. 162:540–551. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kopp F and Mendell JT: Functional
classification and experimental dissection of long noncoding RNAs.
Cell. 172:393–407. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Derrien T, Johnson R, Bussotti G, Tanzer
A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG,
et al: The GENCODE v7 catalog of human long noncoding RNAs:
Analysis of their gene structure, evolution, and expression. Genome
Res. 22:1775–1789. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ulitsky I and Bartel DP: lincRNAs:
Genomics, evolution, and mechanisms. Cell. 154:26–46. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chen F, Chen J, Yang L, Liu J, Zhang X,
Zhang Y, Tu Q, Yin D, Lin D, Wong PP, et al: Extracellular
vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated
macrophages regulates aerobic glycolysis of breast cancer cells.
Nat Cell Biol. 21:498–510. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gao YL, Zhao ZS, Zhang MY, Han LJ, Dong YJ
and Xu B: Long noncoding RNA PVT1 facilitates cervical cancer
progression via negative regulating of miR-424. Oncol Res.
25:1391–1398. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang S, Hui Y, Li X and Jia Q: Silencing
of lncRNA CCDC26 restrains the growth and migration of glioma cells
in vitro and in vivo via targeting miR-203. Oncol Res.
26:1143–1154. 2018. View Article : Google Scholar
|
|
50
|
Li X, Zhang C and Tian Y: Long non-coding
RNA TDRG1 promotes hypoxia-induced glycolysis by targeting the
miR-214-5p/SEMA4C axis in cervical cancer cells. J Mol Histol.
52:245–256. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Xiao L, Wang W, Zhao J, Xu H, Li S and
Yang X: lncRNA MALAT1 promotes cell proliferation and invasion by
regulating the miR-101/EZH2 axis in oral squamous cell carcinoma.
Oncol Lett. 20:1642020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Erratum: Long Non-coding RNA CASC2 serves
as A ceRNA of microRNA-21 to promote pdcd4 expression in oral
squamous cell carcinoma [Corrigendum]. Onco Targets Ther.
12:95692019. View Article : Google Scholar
|
|
53
|
Yu Q, Xiang L, Chen Z, Liu X, Ou H, Zhou J
and Yang D: MALAT1 functions as a competing endogenous RNA to
regulate SMAD5 expression by acting as a sponge for miR-142-3p in
hepatocellular carcinoma. Cell Biosci. 9:392019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Holman GD: Chemical biology probes of
mammalian GLUT structure and function. Biochem J. 475:3511–3534.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Simpson IA, Appel NM, Hokari M, Oki J,
Holman GD, Maher F, Koehler-Stec EM, Vannucci SJ and Smith QR:
Blood-brain barrier glucose transporter: Effects of hypo- and
hyperglycemia revisited. J Neurochem. 72:238–247. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yu M, Yongzhi H, Chen S, Luo X, Lin Y,
Zhou Y, Jin H, Hou B, Deng Y, Tu L and Jian Z: The prognostic value
of GLUT1 in cancers: A systematic review and meta-analysis.
Oncotarget. 8:43356–43367. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Maher F, Vannucci SJ and Simpson IA:
Glucose transporter proteins in brain. FASEB J. 8:1003–1011. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
James DE, Strube M and Mueckler M:
Molecular cloning and characterization of an insulin-regulatable
glucose transporter. Nature. 338:83–87. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Shi Y, Zhang Y, Ran F, Liu J, Lin J, Hao
X, Ding L and Ye Q: Let-7a-5p inhibits triple-negative breast tumor
growth and metastasis through GLUT12-mediated warburg effect.
Cancer Lett. 495:53–65. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Tang R, Yang C, Ma X, Wang Y, Luo D, Huang
C, Xu Z, Liu P and Yang L: MiR-let-7a inhibits cell proliferation,
migration, and invasion by down-regulating PKM2 in gastric cancer.
Oncotarget. 7:5972–5984. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhang T, Zhang Z, Li F, Ping Y, Qin G,
Zhang C and Zhang Y: Correction: miR-143 regulates memory T cell
differentiation by reprogramming T cell metabolism. J Immunol.
201:2165–2175. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Ciscato F, Ferrone L, Masgras I, Laquatra
C and Rasola A: Hexokinase 2 in cancer: A prima donna playing
multiple characters. Int J Mol Sci. 22:47162021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Peschiaroli A, Giacobbe A, Formosa A,
Markert EK, Bongiorno-Borbone L, Levine AJ, Candi E, D'Alessandro
A, Zolla L, Finazzi Agrò A and Melino G: miR-143 regulates
hexokinase 2 expression in cancer cells. Oncogene. 32:797–802.
2013. View Article : Google Scholar
|
|
64
|
Wolf A, Agnihotri S, Micallef J, Mukherjee
J, Sabha N, Cairns R, Hawkins C and Guha A: Hexokinase 2 is a key
mediator of aerobic glycolysis and promotes tumor growth in human
glioblastoma multiforme. J Exp Med. 208:313–326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhou P, Chen WG and Li XW: MicroRNA-143
acts as a tumor suppressor by targeting hexokinase 2 in human
prostate cancer. Am J Cancer Res. 5:2056–2063. 2015.PubMed/NCBI
|
|
66
|
Gregersen LH, Jacobsen A, Frankel LB, Wen
J, Krogh A and Lund AH: MicroRNA-143 down-regulates Hexokinase 2 in
colon cancer cells. BMC Cancer. 12:2322012. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Chen J, Yu Y, Li H, Hu Q, Chen X, He Y,
Xue C, Ren F, Ren Z, Li J, et al: Long non-coding RNA PVT1 promotes
tumor progression by regulating the miR-143/HK2 axis in gallbladder
cancer. Mol Cancer. 18:332019. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Yu T, Li G, Wang C, Gong G, Wang L, Li C,
Chen Y and Wang X: MIR210HG regulates glycolysis, cell
proliferation, and metastasis of pancreatic cancer cells through
miR-125b-5p/HK2/PKM2 axis. RNA Biol. 18:2513–2530. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Li Y, Wang Y, Fan H, Zhang Z and Li N:
miR-125b-5p inhibits breast cancer cell proliferation, migration
and invasion by targeting KIAA1522. Biochem Biophys Res Commun.
504:277–282. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Liu S, Chen Q and Wang Y: MiR-125b-5p
suppresses the bladder cancer progression via targeting HK2 and
suppressing PI3K/AKT pathway. Hum Cell. 33:185–194. 2020.
View Article : Google Scholar
|
|
71
|
Hui L, Zhang J and Guo X: MiR-125b-5p
suppressed the glycolysis of laryngeal squamous cell carcinoma by
down-regulating hexokinase-2. Biomed Pharmacother. 103:1194–1201.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Xu QL, Luo Z, Zhang B, Qin GJ, Zhang RY,
Kong XY, Tang HY and Jiang W: Methylation-associated silencing of
miR-91 promotes nasopharyngeal carcinoma progression and glycolysis
via HK2. Cancer Sci. 112:4127–4138. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Guo W, Qiu Z, Wang Z, Wang Q, Tan N, Chen
T, Chen Z, Huang S, Gu J, Li J, et al: MiR-199a-5p is negatively
associated with malignancies and regulates glycolysis and lactate
production by targeting hexokinase 2 in liver cancer. Hepatology.
62:1132–1144. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Yoshino H, Enokida H, Itesako T, Kojima S,
Kinoshita T, Tatarano S, Chiyomaru T, Nakagawa M and Seki N:
Tumor-suppressive microRNA-143/145 cluster targets hexokinase-2 in
renal cell carcinoma. Cancer Sci. 104:1567–1574. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zhao Y, Zhong R, Deng C and Zhou Z: Circle
RNA circABCB10 modulates PFN2 to promote breast cancer progression,
as well as aggravate radioresistance through facilitating
glycolytic metabolism via miR-223-3p. Cancer Biother Radiopharm.
36:477–490. 2021.
|
|
76
|
Dong P, Xiong Y, Konno Y, Ihira K,
Kobayashi N, Yue J and Watari H: Long non-coding RNA DLEU2 drives
EMT and glycolysis in endometrial cancer through HK2 by
competitively binding with miR-455 and by modulating the
EZH2/miR-181a pathway. J Exp Clin Cancer Res. 40:2162021.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Zhang B, Chen J, Cui M and Jiang Y: LncRNA
ZFAS1/miR-1271-5p/HK2 promotes glioma development through
regulating proliferation, migration, invasion and apoptosis.
Neurochem Res. 45:2828–2839. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Sun L, Wang P, Zhang Z, Zhang K, Xu Z, Li
S and Mao J: MicroRNA-615 functions as a tumor suppressor in
osteosarcoma through the suppression of HK2. Oncol Lett.
20:2262020. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Ye J, Xiao X, Han Y, Fan D, Zhu Y and Yang
L: MiR-3662 suppresses cell growth, invasion and glucose metabolism
by targeting HK2 in hepatocellular carcinoma cells. Neoplasma.
67:773–781. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Li C, Yu Z and Ye J: MicroRNA-513a-3p
regulates colorectal cancer cell metabolism via targeting
hexokinase 2. Exp Ther Med. 20:572–580. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Ding Z, Guo L, Deng Z and Li P: Circ-PRMT5
enhances the proliferation, migration and glycolysis of hepatoma
cells by targeting miR-188-5p/HK2 axis. Ann Hepatol. 19:269–279.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Jia KG, Feng G, Tong YS, Tao GZ and Xu L:
miR-206 regulates non-small-cell lung cancer cell aerobic
glycolysis by targeting hexokinase 2. J Biochem. 167:365–370. 2020.
View Article : Google Scholar
|
|
83
|
Wang J, Chen J, Sun F, Wang Z, Xu W, Yu Y,
Ding F and Shen H: miR-202 functions as a tumor suppressor in
hepatocellular carcinoma by targeting HK2. Oncology Lett.
19:2265–2271. 2020.
|
|
84
|
Liu C, Cai L and Li H: miR-185 regulates
the growth of osteosarcoma cells via targeting Hexokinase 2. Mol
Med Rep. 20:2774–2782. 2019.PubMed/NCBI
|
|
85
|
Xu F, Yan JJ, Gan Y, Chang Y, Wang HL, He
XX and Zhao Q: miR-885-5p negatively regulates warburg effect by
silencing hexokinase 2 in liver cancer. Mol Ther Nucleic Acids.
18:308–319. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Lu J, Wang L, Chen W, Wang Y, Zhen S, Chen
H, Cheng J, Zhou Y, Li X and Zhao L: miR-603 targeted hexokinase-2
to inhibit the malignancy of ovarian cancer cells. Arch Biochem
Biophys. 661:1–9. 2019. View Article : Google Scholar
|
|
87
|
Liu Y, Huo Y, Wang D, Tai Y, Li J, Pang D,
Zhang Y, Zhao W, Du N and Huang Y: MiR-216a-5p/Hexokinase 2 axis
regulates uveal melanoma growth through modulation of Warburg
effect. Biochem Biophys Res Commun. 501:885–892. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Zhu W, Huang Y, Pan Q, Xiang P, Xie N and
Yu H: MicroRNA-98 Suppress Warburg Effect by Targeting HK2 in Colon
Cancer Cells. Dig Dis Sci. 62:660–668. 2017. View Article : Google Scholar
|
|
89
|
Li LQ, Yang Y, Chen H, Zhang L, Pan D and
Xie WJ: MicroRNA-181b inhibits glycolysis in gastric cancer cells
via targeting hexokinase 2 gene. Cancer Biomark. 17:75–81. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Zhang K, Zhang M, Jiang H, Liu F, Liu H
and Li Y: Down-regulation of miR-214 inhibits proliferation and
glycolysis in non-small-cell lung cancer cells via down-regulating
the expression of hexokinase 2 and pyruvate kinase isozyme M2.
Biomed Pharmacother. 105:545–552. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Kim J, Park MW, Park YJ, Ahn JW, Sim JM,
Kim S, Heo J, Jeong JH, Lee M, Lim J and Moon JS: miR-542-3p
Contributes to the HK2-mediated high glycolytic phenotype in human
glioma cells. Genes. 12:6332021. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Atsumi T, Chesney J, Metz C, Leng L,
Donnelly S, Makita Z, Mitchell R and Bucala R: High expression of
inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase
(iPFK-2; PFKFB3) in human cancers. Cancer Res. 62:5881–5887.
2002.PubMed/NCBI
|
|
93
|
Boscaro C, Baggio C, Carotti M, Sandonà D,
Trevisi L, Cignarella A and Bolego C: Targeting of PFKFB3 with
miR-206 but not mir-26b inhibits ovarian cancer cell proliferation
and migration involving FAK downregulation. FASEB J. 36:e221402022.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Ge X, Lyu P, Cao Z, Li J, Guo G, Xia W and
Gu Y: Overexpression of miR-206 suppresses glycolysis,
proliferation and migration in breast cancer cells via PFKFB3
targeting. Biochem Biophys Res Commun. 463:1115–1121. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Deng X, Li D, Ke X, Wang Q, Yan S, Xue Y,
Wang Q and Zheng H: Mir-488 alleviates chemoresistance and
glycolysis of colorectal cancer by targeting PFKFB3. J Clin Lab
Anal. 35:e235782021. View Article : Google Scholar
|
|
96
|
Wang J, Li X, Xiao Z, Wang Y, Han Y, Li J,
Zhu W, Leng Q, Wen Y and Wen X: MicroRNA-488 inhibits proliferation
and glycolysis in human prostate cancer cells by regulating PFKFB3.
FEBS Open Bio. 9:1798–1807. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Chen L and Cao Y, Wu B and Cao Y:
MicroRNA-3666 suppresses cell growth in head and neck squamous cell
carcinoma through inhibition of PFKFB3-mediated warburg effect.
Onco Targets Ther. 13:9029–9041. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Du JY, Wang LF, Wang Q and Yu LD: miR-26b
inhibits proliferation, migration, invasion and apoptosis induction
via the downregulation of
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 driven
glycolysis in osteosarcoma cells. Oncol Rep. 33:1890–1898. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Sheng W, Xu W, Ding J, Li L, You X, Wu Y
and He Q: Curcumol inhibits the malignant progression of prostate
cancer and regulates the PDK1/AKT/mTOR pathway by targeting miR-9.
Oncol Rep. 46:2462021. View Article : Google Scholar :
|
|
100
|
Qian Y, Wu X, Wang H, Hou G, Han X and
Song W: MicroRNA-4290 suppresses PDK1-mediated glycolysis to
enhance the sensitivity of gastric cancer cell to cisplatin. Braz J
Med Biol Res. 53:e93302020. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Tsukamoto Y, Nakada C, Noguchi T, Tanigawa
M, Nguyen LT, Uchida T, Hijiya N, Matsuura K, Fujioka T, Seto M and
Moriyama M: MicroRNA-375 is downregulated in gastric carcinomas and
regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer
Res. 70:2339–2349. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Jia-Yuan X, Wei S, Fang-Fang L, Zhi-Jian
D, Long-He C and Sen L: miR-375 inhibits the proliferation and
invasion of nasopharyngeal carcinoma cells by suppressing PDK1.
Biomed Res Int. 2020:97042452020. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Qu C, Yan C, Cao W, Li F, Qu Y, Guan K, Si
C, Yu Z and Qu Z: miR-128-3p contributes to mitochondrial
dysfunction and induces apoptosis in glioma cells via targeting
pyruvate dehydrogenase kinase 1. IUBMB Life. 72:465–475. 2020.
View Article : Google Scholar
|
|
104
|
Huang Y, Zheng S, Lin Y and Ke L: Circular
RNA circ-ERBB2 elevates the warburg effect and facilitates
triple-negative breast cancer growth by the MicroRNA
136-5p/pyruvate dehydrogenase Kinase 4 axis. Mol Cell Biol.
41:e00609202021. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Zhao Z, Ji M, Wang Q, He N and Li Y:
miR-16-5p/PDK4-mediated metabolic reprogramming is involved in
chemoresistance of cervical cancer. Mol Ther Oncolytics.
17:509–517. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Guda MR, Asuthkar S, Labak CM, Tsung AJ,
Alexandrov I, Mackenzie MJ, Prasad DV and Velpula KK: Targeting
PDK4 inhibits breast cancer metabolism. Am J Cancer Res.
8:1725–1738. 2018.PubMed/NCBI
|
|
107
|
Si T, Ning X, Zhao H, Zhang M, Huang P, Hu
Z, Yang L and Lin L: microRNA-9-5p regulates the mitochondrial
function of hepatocellular carcinoma cells through suppressing
PDK4. Cancer Gene Ther. 28:706–718. 2021. View Article : Google Scholar
|
|
108
|
Miao Y, Li Q, Sun G, Wang L, Zhang D, Xu H
and Xu Z: MiR-5683 suppresses glycolysis and proliferation through
targeting pyruvate dehydrogenase kinase 4 in gastric cancer. Cancer
Med. 9:7231–7243. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Feng L, Cheng K, Zang R, Wang Q and Wang
J: miR-497-5p inhibits gastric cancer cell proliferation and growth
through targeting PDK3. Biosci Rep. 39:BSR201906542019. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Cheung EC and Vousden KH: The role of p53
in glucose metabolism. Curr Opin Cell Biol. 22:186–191. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Yang L, Zhang B, Wang X, Liu Z, Li J,
Zhang S, Gu X, Jia M, Guo H, Feng N, et al: P53/PANK1/miR-107
signalling pathway spans the gap between metabolic reprogramming
and insulin resistance induced by high-fat diet. J Cell Mol Med.
24:3611–3624. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B,
Korzh V, Lodish HF and Lim B: MicroRNA-125b is a novel negative
regulator of p53. Genes Dev. 23:862–876. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Gopu V, Fan L, Shetty RS, Nagaraja MR and
Shetty S: Caveolin-1 scaffolding domain peptide regulates glucose
metabolism in lung fibrosis. JCI Insight. 5:e1379692020. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Zou S, Rao Y and Chen W: miR-885-5p plays
an accomplice role in liver cancer by instigating TIGAR expression
via targeting its promoter. Biotechnol Appl Biochem. 66:763–771.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Tang J, Chen L, Qin ZH and Sheng R:
Structure, regulation, and biological functions of TIGAR and its
role in diseases. Acta Pharmacol Sin. 42:1547–1555. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Jones M and Lal A: MicroRNAs, wild-type
and mutant p53: More questions than answers. RNA Biol. 9:781–791.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Dang CV: MYC on the path to cancer. Cell.
149:22–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Broecker-Preuss M, Becher-Boveleth N,
Bockisch A, Dührsen U and Müller S: Regulation of glucose uptake in
lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways
and impact of glycolytic pathways on cell viability. J Transl Med.
15:1582017. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Zhai S, Xu Z, Xie J, Zhang J, Wang X, Peng
C, Li H, Chen H, Shen B and Deng X: Epigenetic silencing of LncRNA
LINC00261 promotes c-myc-mediated aerobic glycolysis by regulating
miR-222-3p/HIPK2/ERK axis and sequestering IGF2BP1. Oncogene.
40:277–291. 2021. View Article : Google Scholar :
|
|
120
|
Ebron JS, Shankar E, Singh J, Sikand K,
Weyman CM, Gupta S, Lindner DJ, Liu X, Campbell MJ and Shukla GC:
MiR-644a disrupts oncogenic transformation and warburg effect by
direct modulation of multiple genes of tumor-promoting pathways.
Cancer Res. 79:1844–1856. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Luan W, Wang Y, Chen X, Shi Y, Wang J,
Zhang J, Qian J, Li R, Tao T, Wei W, et al: PKM2 promotes glucose
metabolism and cell growth in gliomas through a mechanism involving
a let-7a/ c-Myc/hnRNPA1 feedback loop. Oncotarget. 6:13006–13018.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Wang H, Wang L, Pan H, Wang Y, Shi M, Yu
H, Wang C, Pan X and Chen Z: Exosomes derived from macrophages
enhance aerobic glycolysis and chemoresistance in lung cancer by
stabilizing c-Myc via the Inhibition of NEDD4L. Front Cell Dev
Biol. 8:6206032020. View Article : Google Scholar
|
|
123
|
Kim S, Lee E, Jung J, Lee JW, Kim HJ, Kim
J, Yoo HJ, Lee HJ, Chae SY, Jeon SM, et al: microRNA-155 positively
regulates glucose metabolism via PIK3R1-FOXO3a-cMYC axis in breast
cancer. Oncogene. 37:2982–2991. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Ojuka EO: Role of calcium and AMP kinase
in the regulation of mitochondrial biogenesis and GLUT4 levels in
muscle. Proc Nutr Soc. 63:275–278. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Shackelford DB and Shaw RJ: The LKB1-AMPK
pathway: Metabolism and growth control in tumour suppression. Nat
Rev Cancer. 9:563–575. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Hardie DG: AMP-activated/SNF1 protein
kinases: Conserved guardians of cellular energy. Nat Rev Mol Cell
Biol. 8:774–785. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Lyu X, Wang J, Guo X, Wu G, Jiao Y, Faleti
OD, Liu P, Liu T, Long Y, Chong T, et al: EBV-miR-BART1-5P
activates AMPK/mTOR/HIF1 pathway via a PTEN independent manner to
promote glycolysis and angiogenesis in nasopharyngeal carcinoma.
PLoS Pathog. 14:e10074842018. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Barisciano G, Colangelo T, Rosato V,
Muccillo L, Taddei ML, Ippolito L, Chiarugi P, Galgani M,
Bruzzaniti S, Matarese G, et al: miR-27a is a master regulator of
metabolic reprogramming and chemoresistance in colorectal cancer.
Br J Cancer. 122:1354–1366. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Zhaohui W, Yingli N, Hongli L, Haijing W,
Xiaohua Z, Chao F, Liugeng W, Hui Z, Feng T, Linfeng Y and Hong J:
Amentoflavone induces apoptosis and suppresses glycolysis in glioma
cells by targeting miR-124-3p. Neurosci Lett. 686:1–9. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Wang L, Guo W, Ma J, Dai W, Liu L, Guo S,
Chen J, Wang H, Yang Y, Yi X, et al: Aberrant SIRT6 expression
contributes to melanoma growth: Role of the autophagy paradox and
IGF-AKT signaling. Autophagy. 14:518–533. 2018. View Article : Google Scholar :
|
|
131
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
132
|
Sun Y, Liu W, Zhao Q, Zhang R, Wang J, Pan
P, Shang H, Liu C and Wang C: Down-regulating the expression of
miRNA-21 inhibits the glucose metabolism of A549/DDP cells and
promotes cell death through the PI3K/AKT/mTOR/HIF-1α pathway. Front
Oncol. 11:6535962021. View Article : Google Scholar
|
|
133
|
Pan C, Liu Q and Wu X:
HIF1α/miR-520a-3p/AKT1/mTOR feedback promotes the proliferation and
glycolysis of gastric cancer cells. Cancer Manage Res.
11:10145–10156. 2019. View Article : Google Scholar
|
|
134
|
Wang Q, Liu MJ, Bu J, Deng JL, Jiang BY,
Jiang LD and He XJ: miR-485-3p regulated by MALAT1 inhibits
osteosarcoma glycolysis and metastasis by directly suppressing
c-MET and AKT3/mTOR signalling. Life Sci. 268:1189252021.
View Article : Google Scholar
|
|
135
|
Carnero A, Blanco-Aparicio C, Renner O,
Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer,
therapeutic implications. Curr Cancer Drug Targets. 8:187–198.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Zhai Z, Mu T, Zhao L, Li Y, Zhu D and Pan
Y: MiR-181a-5p facilitates proliferation, invasion, and glycolysis
of breast cancer through NDRG2-mediated activation of PTEN/AKT
pathway. Bioengineered. 13:83–95. 2022. View Article : Google Scholar :
|
|
137
|
Liu W, Kang L, Han J, Wang Y, Shen C, Yan
Z, Tai Y and Zhao C: miR-342-3p suppresses hepatocellular carcinoma
proliferation through inhibition of IGF-1R-mediated Warburg effect.
Onco Targets Ther. 11:1643–1653. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Wang B, Sun F, Dong N, Sun Z, Diao Y,
Zheng C, Sun J, Yang Y and Jiang D: MicroRNA-7 directly targets
insulin-like growth factor 1 receptor to inhibit cellular growth
and glucose metabolism in gliomas. Diagn Pathol. 9:2112014.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Xu H, Sun X, Huang Y, Si Q and Li M: Long
non-coding RNA NEAT1 modifies cell proliferation, colony formation,
apoptosis, migration and invasion via the miR-4500/BZW1 axis in
ovarian cancer. Mol Med Rep. 22:3347–3357. 2020.PubMed/NCBI
|
|
140
|
Xu M, Zhou K, Wu Y, Wang L and Lu S:
Linc00161 regulated the drug resistance of ovarian cancer by
sponging microRNA-128 and modulating MAPK1. Mol Carcinog.
58:577–587. 2019. View Article : Google Scholar
|
|
141
|
Zhao J, Li D and Fang L: MiR-128-3p
suppresses breast cancer cellular progression via targeting LIMK1.
Biomed Pharmacother. 115:1089472019. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Liu Y, Fu X, Wang X, Liu Y and Song X:
Long non-coding RNA OIP5-AS1 facilitates the progression of ovarian
cancer via the miR-128-3p/CCNG1 axis. Mol Med Rep. 23:3882021.
View Article : Google Scholar :
|
|
143
|
Liu Y, He X, Chen Y and Cao D: Long
non-coding RNA LINC00504 regulates the Warburg effect in ovarian
cancer through inhibition of miR-1244. Mol Cell Biochem. 464:39–50.
2020. View Article : Google Scholar
|
|
144
|
Goto H, Nishio M, To Y, Oishi T, Miyachi
Y, Maehama T, Nishina H, Akiyama H, Mak TW, Makii Y, et al: Loss of
Mob1a/b in mice results in chondrodysplasia due to YAP1/
TAZ-TEAD-dependent repression of SOX9. Development.
145:dev1592442018. View Article : Google Scholar
|
|
145
|
Wu DW, Wang YC, Wang L, Chen CY and Lee H:
A low microRNA-630 expression confers resistance to tyrosine kinase
inhibitors in EGFR-mutated lung adenocarcinomas via
miR-630/YAP1/ERK feedback loop. Theranostics. 8:1256–1269. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Lin X, Feng D, Li P and Lv Y: LncRNA
LINC00857 regulates the progression and glycolysis in ovarian
cancer by modulating the Hippo signaling pathway. Cancer Med.
9:8122–8132. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Teng Y, Zhang Y, Qu K, Yang X, Fu J, Chen
W and Li X: MicroRNA-29B (mir-29b) regulates the Warburg effect in
ovarian cancer by targeting AKT2 and AKT3. Oncotarget.
6:40799–40814. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Young CD, Nolte EC, Lewis A, Serkova NJ
and Anderson SM: Activated Akt1 accelerates MMTV-c-ErbB2 mammary
tumourigenesis in mice without activation of ErbB3. Br Cancer Res.
10:R702008. View Article : Google Scholar
|
|
149
|
Kotowski K, Rosik J, Machaj F, Supplitt S,
Wiczew D, Jabłońska K, Wiechec E, Ghavami S and Dzięgiel P: Role of
PFKFB3 and PFKFB4 in cancer: Genetic basis, impact on disease
development/progression, and potential as therapeutic targets.
Cancers. 13:9092021. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Mondal S, Roy D, Sarkar Bhattacharya S,
Jin L, Jung D, Zhang S, Kalogera E, Staub J, Wang Y, Xuyang W, et
al: Therapeutic targeting of PFKFB3 with a novel glycolytic
inhibitor PFK158 promotes lipophagy and chemosensitivity in
gynecologic cancers. Int J Cancer. 144:178–189. 2019. View Article : Google Scholar
|
|
151
|
Chakraborty PK, Mustafi SB, Xiong X,
Dwivedi SKD, Nesin V, Saha S, Zhang M, Dhanasekaran D, Jayaraman M,
Mannel R, et al: MICU1 drives glycolysis and chemoresistance in
ovarian cancer. Nat Commun. 8:146342017. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Singh R, Yadav V, Kumar S and Saini N:
MicroRNA-195 inhibits proliferation, invasion and metastasis in
breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1.
Sci Rep. 5:174542015. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Yang Y, Li M, Chang S, Wang L, Song T, Gao
L, Hu L, Li Z, Liu L, Yao J and Huang C: MicroRNA-195 acts as a
tumor suppressor by directly targeting Wnt3a in HepG2
hepatocellular carcinoma cells. Mol Med Rep. 10:2643–2648. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Rao G, Dwivedi SKD, Zhang Y, Dey A,
Shameer K, Karthik R, Srikantan S, Hossen MN, Wren JD, Madesh M, et
al: MicroRNA-195 controls MICU1 expression and tumor growth in
ovarian cancer. EMBO Rep. 21:e484832020. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Cao HL, Liu ZJ, Huang PL, Yue YL and Xi
JN: lncRNA-RMRP promotes proliferation, migration and invasion of
bladder cancer via miR-206. Eur Rev Med Pharmacol Sci.
23:1012–1021. 2019.PubMed/NCBI
|
|
156
|
Hongfeng Z, Andong J, Liwen S, Mingping B,
Xiaowei Y, Mingyong L and Aimin Y: lncRNA RMRP knockdown suppress
hepatocellular carcinoma biological activities via regulation
miRNA-206/TACR1. J Cell Biochem. 121:1690–1702. 2020. View Article : Google Scholar
|
|
157
|
Li L, Zeng S, Guo L, Huang P, Xi J, Feng
J, Li Q, Li Y, Xiao X, Yan R and Zhang J: Long noncoding RNA RMRP
contributes to paclitaxel sensitivity of ovarian cancer by
regulating miR-580-3p/MICU1 signaling. J Oncol.
2022:83019412022.PubMed/NCBI
|
|
158
|
Han RL, Wang FP, Zhang PA, Zhou XY and Li
Y: miR-383 inhibits ovarian cancer cell proliferation, invasion and
aerobic glycolysis by targeting LDHA. Neoplasma. 64:244–252. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Rafat M, Moraghebi M, Afsa M and
Malekzadeh K: The outstanding role of miR-132-3p in carcinogenesis
of solid tumors. Hum Cell. 34:1051–1065. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Cooper SJ, von Roemeling CA, Kang KH,
Marlow LA, Grebe SK, Menefee ME, Tun HW, Colon-Otero G, Perez EA
and Copland JA: Reexpression of tumor suppressor, sFRP1, leads to
antitumor synergy of combined HDAC and methyltransferase inhibitors
in chemoresistant cancers. Mol Cancer Ther. 11:2105–2115. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Hu J, Zhao W, Huang Y, Wang Z, Jiang T and
Wang L: MiR-1180 from bone marrow MSCs promotes cell proliferation
and glycolysis in ovarian cancer cells via SFRP1/Wnt pathway.
Cancer Cell Int. 19:662019. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Gu ZW, He YF, Wang WJ, Tian Q and Di W:
MiR-1180 from bone marrow-derived mesenchymal stem cells induces
glycolysis and chemoresistance in ovarian cancer cells by
upregulating the Wnt signaling pathway. J Zhejiang Univ Sci B.
20:219–237. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Xiaohong Z, Lichun F, Na X, Kejian Z,
Xiaolan X and Shaosheng W: MiR-203 promotes the growth and
migration of ovarian cancer cells by enhancing glycolytic pathway.
Tumour Biol. 37:14989–14997. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Shao X, Zheng X, Ma D, Liu Y and Liu G:
Inhibition of lncRNA-NEAT1 sensitizes 5-Fu resistant cervical
cancer cells through de-repressing the microRNA-34a/LDHA axis.
Biosci Rep. 41:BSR202005332021. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Li L, Ma Y, Maerkeya K, Reyanguly D and
Han L: LncRNA OIP5-AS1 regulates the warburg effect through
miR-124-5p/IDH2/HIF-1α pathway in cervical cancer. Front Cell Dev
Biol. 9:6550182021. View Article : Google Scholar
|
|
166
|
Luo W, Zhang D, Ma S, Wang C, Zhang Q,
Wang H, He K and Liu Z: miR-27a is highly expressed in H1650 cancer
stem cells and regulates proliferation, migration, and invasion. J
Cancer Res Ther. 14(Suppl): S1004–S1011. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Jiang G, Shi W, Fang H and Zhang X:
miR-27a promotes human breast cancer cell migration by inducing EMT
in a FBXW7-dependent manner. Mol Med Rep. 18:5417–5426.
2018.PubMed/NCBI
|
|
168
|
Li W, Yu ZX and Ma BF: The increase of
miR-27a affects the role of cisplatin on proliferation and
migration capacities of liver cancer cells. Eur Rev Med Pharmacol
Sci. 22:5490–5498. 2018.PubMed/NCBI
|
|
169
|
Li P, Zhang Q and Tang H: INPP1
up-regulation by miR-27a contributes to the growth, migration and
invasion of human cervical cancer. J Cell Mol Med. 23:7709–7716.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Zhang S, Chen P, Huang Z, Hu X, Chen M, Hu
S, Hu Y and Cai T: Sirt7 promotes gastric cancer growth and
inhibits apoptosis by epigenetically inhibiting miR-34a. Sci Rep.
5:97872015. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Gougelet A, Sartor C, Bachelot L, Godard
C, Marchiol C, Renault G, Tores F, Nitschke P, Cavard C, Terris B,
et al: Antitumour activity of an inhibitor of miR-34a in liver
cancer with β-catenin-mutations. Gut. 65:1024–1034. 2016.
View Article : Google Scholar
|
|
172
|
Hermeking H: The miR-34 family in cancer
and apoptosis. Cell Death Differ. 17:193–199. 2010. View Article : Google Scholar
|
|
173
|
Zhang R, Su J, Xue SL, Yang H, Ju LL, Ji
Y, Wu KH, Zhang YW, Zhang YX, Hu JF and Yu MM: HPV E6/p53 mediated
down-regulation of miR-34a inhibits Warburg effect through
targeting LDHA in cervical cancer. Am J Cancer Res. 6:312–320.
2016.PubMed/NCBI
|
|
174
|
Yang H, Wu XL, Wu KH, Zhang R, Ju LL, Ji
Y, Zhang YW, Xue SL, Zhang YX, Yang YF and Yu MM: MicroRNA-497
regulates cisplatin chemosensitivity of cervical cancer by
targeting transketolase. Am J Cancer Res. 6:2690–2699.
2016.PubMed/NCBI
|
|
175
|
Yang X and Wu X: miRNA expression profile
of vulvar squamous cell carcinoma and identification of the
oncogenic role of miR-590-5p. Oncol Rep. 35:398–408. 2016.
View Article : Google Scholar
|
|
176
|
de Melo Maia B, Lavorato-Rocha AM,
Rodrigues LS, Coutinho-Camillo CM, Baiocchi G, Stiepcich MM, Puga
R, de A Lima L, Soares FA and Rocha RM: microRNA portraits in human
vulvar carcinoma. Cancer Prev Res (Phila). 6:1231–1241. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Gonzalez Dos Anjos L, de Almeida BC, Gomes
de Almeida T, Mourão Lavorato Rocha A, De Nardo Maffazioli G,
Soares FA, Werneck da Cunha I, Baracat EC and Carvalho KC: Could
miRNA signatures be useful for predicting uterine sarcoma and
carcinosarcoma prognosis and treatment? Cancers (Basel).
10:3152018. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Tyagi K, Mandal S and Roy A: Recent
advancements in therapeutic targeting of the Warburg effect in
refractory ovarian cancer: A promise towards disease remission.
Biochim Biophys Acta Rev Cancer. 1876:1885632021. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Hietanen S, Lain S, Krausz E, Blattner C
and Lane DP: Activation of p53 in cervical carcinoma cells by small
molecules. Proc Natl Acad Sci USA. 97:8501–8506. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Guan XY, Guan XL and Jiao ZY: Improving
therapeutic resistance: Beginning with targeting the tumor
microenvironment. J Chemother. 34:492–516. 2022. View Article : Google Scholar
|
|
181
|
Arvizo RR, Moyano DF, Saha S, Thompson MA,
Bhattacharya R, Rotello VM, Prakash YS and Mukherjee P: Probing
novel roles of the mitochondrial uniporter in ovarian cancer cells
using nanoparticles. J Biol Chem. 288:17610–17618. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Khan S, Chib R, Shah BA, Wani ZA, Dhar N,
Mondhe DM, Lattoo S, Jain SK, Taneja SC and Singh J: A cyano
analogue of boswellic acid induces crosstalk between p53/PUMA/Bax
and telomerase that stages the human papillomavirus type 18
positive HeLa cells to apoptotic death. Eur J Pharmacol.
660:241–248. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Yuan Y, Li H, Pu W, Chen L, Guo D, Jiang
H, He B, Qin S, Wang K, Li N, et al: Cancer metabolism and tumor
microenvironment: Fostering each other? Sci China Life Sci.
65:236–279. 2022. View Article : Google Scholar
|
|
184
|
Hashemian SM, Pourhanifeh MH, Fadaei S,
Velayati AA, Mirzaei H and Hamblin MR: Non-coding RNAs and
exosomes: Their role in the pathogenesis of sepsis. Mol Ther
Nucleic Acids. 21:51–74. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Razavi ZS, Tajiknia V, Majidi S, Ghandali
M, Mirzaei HR, Rahimian N, Hamblin MR and Mirzaei H: Gynecologic
cancers and non-coding RNAs: Epigenetic regulators with emerging
roles. Crit Rev Oncol Hematol. 157:1031922021. View Article : Google Scholar
|
|
186
|
Bonneau E, Neveu B, Kostantin E, Tsongalis
GJ and De Guire V: How close are miRNAs from clinical practice? A
perspective on the diagnostic and therapeutic market. EJIFCC.
30:114–127. 2019.PubMed/NCBI
|
|
187
|
Fatmi A, Chabni N, Cernada M, Vento M,
González-López M, Aribi M, Pallardó FV and García-Giménez JL:
Clinical and immunological aspects of microRNAs in neonatal sepsis.
Biomed Pharmacother. 145:1124442022. View Article : Google Scholar
|
|
188
|
Gumusoglu-Acar E, Gunel T, Hosseini MK,
Dogan B, Tekarslan EE, Gurdamar B, Cevik N, Sezerman U, Topuz S and
Aydinli K: Metabolic pathways of potential miRNA biomarkers derived
from liquid biopsy in epithelial ovarian cancer. Oncol Lett.
25:1422023. View Article : Google Scholar : PubMed/NCBI
|
